Your browser version may not work well with NCBI's Web applications. More information here...
1: Clin Oncol (R Coll Radiol). 2005 May;17(3):174-84.Links

What's new in the management of cutaneous T-cell lymphoma?

McFarlane V, Friedmann PS, Illidge TM.

Southampton Oncology Centre, Southampton University NHS Trust, Southampton S016 6YD, UK.

The aetiology and clinical management of primary cutaneous T-cell lymphoma (CTCL) and specifically of mycosis fungoides and Sezary syndrome are poorly defined. Interesting new insights into CTCL disease biology as well as a number of emerging of novel therapeutic interventions make this an increasingly interesting area for dermatologists and oncologists involved in the treatment of CTCL. This review article covers much of this new information including new drugs, such as denileukin diftitox (Ontak) a targeted cytotoxic biological agent, Bexarotene an RXR selective retinoid, anti-CD4 monoclonal antibodies (mAb), new cytotoxics agents and vaccines.

PMID: 15901002 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Bexarotene (Targretin® )

    Bexarotene is used to treat cutaneous T-cell lymphoma (CTCL, a type of skin cancer) in people whose disease could not be treated successfully with at least one other medication. Bexarotene is in a class of medications ca...

  • Source: AHFS Consumer Medication Information